380 related articles for article (PubMed ID: 22371149)
1. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry of P2 and adenosine receptors: Common scaffolds adapted for multiple targets.
Jacobson KA; IJzerman AP; Müller CE
Biochem Pharmacol; 2021 May; 187():114311. PubMed ID: 33130128
[TBL] [Abstract][Full Text] [Related]
4. Purine and pyrimidine receptors.
Burnstock G
Cell Mol Life Sci; 2007 Jun; 64(12):1471-83. PubMed ID: 17375261
[TBL] [Abstract][Full Text] [Related]
5. New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2.
Baraldi PG; Romagnoli R; Tabrizi MA; Bovero A; Preti D; Fruttarolo F; Moorman AR; Borea PA
Farmaco; 2005 Mar; 60(3):185-202. PubMed ID: 15784237
[TBL] [Abstract][Full Text] [Related]
6. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
7. Ribose modified nucleosides and nucleotides as ligands for purine receptors.
Jacobson KA; Ravi RG; Nandanan E; Kim HS; Moro S; Kim YC; Lee K; Barak D; Marquez VE; Ji XD
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):333-41. PubMed ID: 11563046
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in adenosine receptor ligands and their potential as novel drugs.
Müller CE; Jacobson KA
Biochim Biophys Acta; 2011 May; 1808(5):1290-308. PubMed ID: 21185259
[TBL] [Abstract][Full Text] [Related]
9. Tools and drugs for uracil nucleotide-activated P2Y receptors.
Rafehi M; Müller CE
Pharmacol Ther; 2018 Oct; 190():24-80. PubMed ID: 29660366
[TBL] [Abstract][Full Text] [Related]
10. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.
Jacobson KA
J Med Chem; 2013 May; 56(10):3749-67. PubMed ID: 23597047
[TBL] [Abstract][Full Text] [Related]
11. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
[TBL] [Abstract][Full Text] [Related]
12. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).
Jacobson KA
Bioconjug Chem; 2009 Oct; 20(10):1816-35. PubMed ID: 19405524
[TBL] [Abstract][Full Text] [Related]
13. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.
Deb PK; Deka S; Borah P; Abed SN; Klotz KN
Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094
[TBL] [Abstract][Full Text] [Related]
14. Purinergic signalling in brain ischemia.
Pedata F; Dettori I; Coppi E; Melani A; Fusco I; Corradetti R; Pugliese AM
Neuropharmacology; 2016 May; 104():105-30. PubMed ID: 26581499
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Role of N
Petrelli R; Scortichini M; Kachler S; Boccella S; Cerchia C; Torquati I; Del Bello F; Salvemini D; Novellino E; Luongo L; Maione S; Jacobson KA; Lavecchia A; Klotz KN; Cappellacci L
J Med Chem; 2017 May; 60(10):4327-4341. PubMed ID: 28447789
[TBL] [Abstract][Full Text] [Related]
16. GPR17: molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors.
Parravicini C; Ranghino G; Abbracchio MP; Fantucci P
BMC Bioinformatics; 2008 Jun; 9():263. PubMed ID: 18533035
[TBL] [Abstract][Full Text] [Related]
17. Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats.
Ham M; Mizumori M; Watanabe C; Wang JH; Inoue T; Nakano T; Guth PH; Engel E; Kaunitz JD; Akiba Y
J Pharmacol Exp Ther; 2010 Dec; 335(3):607-13. PubMed ID: 20805305
[TBL] [Abstract][Full Text] [Related]
18. Beneficial and detrimental role of adenosine signaling in diseases and therapy.
Liu H; Xia Y
J Appl Physiol (1985); 2015 Nov; 119(10):1173-82. PubMed ID: 26316513
[TBL] [Abstract][Full Text] [Related]
19. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways.
Agarwal R; Agarwal P
Expert Opin Ther Targets; 2014 May; 18(5):527-39. PubMed ID: 24579961
[TBL] [Abstract][Full Text] [Related]
20. Introduction to adenosine receptors as therapeutic targets.
Jacobson KA
Handb Exp Pharmacol; 2009; (193):1-24. PubMed ID: 19639277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
